The Efficacy and Safety of PAZ320 on PPG and Insulin Blood Levels in Type II Diabetic Patients (PAZ320)
Primary Purpose
Type II Diabetes
Status
Withdrawn
Phase
Phase 2
Locations
France
Study Type
Interventional
Intervention
PAZ320
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Type II Diabetes focused on measuring PAZ320, Type II diabetes, Metformin, Galactomannan
Eligibility Criteria
Inclusion Criteria:
- Patients diagnosed with type II diabetes since at least one year, not presenting any complications of their disease.
- Patients under treatment with Metformin up to 3g/day, given twice or three times daily. Metformin doses should not exceed 3g/day, and should be well tolerated by the patients, its dose should have been stable for the last 3 months before inclusion in the study. Metformin should be taken in the morning of the visit only after the test meal is taken. The next doses of metformin will be taken with meals after the visit, in the habitual order the patient is used to take. The patients should not stop taking metformin during the study, but continue as usual, except that in the mornings of the visits, as the patients arrive in fasting conditions, metformin should be taken after the test meal. If a concomitant combination with an oral anti diabetic agent is given, because of elevated HbA1c levels, it should be taken together with metformin after the test meal.
- Age - between 35 and 65, male and female.
- Females should not be pregnant or breast feeding, women of child bearing potential should guarantee anti-contraceptive measures.
- BMI (body mass index) - between 25 and 32.
- Patients with glycated hemoglobin (HbA1c) lower than 9%, and higher than 6.5%, HbA1c will be determined in the first visit.
- Patients who are able to collaborate during the entire duration of the study.
Exclusion Criteria:
- Patients with other underlying diseases, such as cardiovascular disease, renal disease, peripheral vascular disease or any condition considered to be a complication of diabetes, should be excluded from this study.
- Patients treated with insulin subcutaneous injections or with GLP-1 agonists, or by alpha-glucosidase inhibitors or by glinides should not be included in the study.
- HbA1c higher than 9%, or lower than 6.5%
- Women who are either pregnant or lactating
- Participation in another clinical study in the month preceding recruitment into the study.
- Patients who cannot guarantee compliance.
Sites / Locations
- Department of Internal Medicine, Infectious Diseases and Diabetology Hopital Robert Bisson (Lisieux)
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Placebo Comparator
Experimental
Experimental
Arm Label
A - Placebo Control
B - PAZ320 Low Dose
C - PAZ320 High Dose
Arm Description
4 tablets of placebo
2 tablets of PAZ320 and 2 tablet of placebo
4 tablet of PAZ320
Outcomes
Primary Outcome Measures
Assess the PAZ320 effect on postprandial blood glucose levels in type II diabetic patients.
The extent and duration of PAZ320 effect on postprandial blood glucose levels in type II diabetic patients will be assessed under treatment with metformin, over 4 hours after the intake of a standard meal, using an implanted continuous glucose monitoring device.
Secondary Outcome Measures
Number of Subjects with Adverse Events as a Measure of Safety and Tolerability
The secondary safety endpoint is number subjects with occurrences of following AEs: injury, surgery, accidents, or illnesses, and significant abnormalities in clinical laboratory values, psychological testing, or physical examination findings. In cases of surgical or diagnostic procedures, the condition/illness leading to such a procedure will be considered as the AE rather than the procedure itself.
Full Information
NCT ID
NCT04569214
First Posted
November 13, 2013
Last Updated
September 24, 2020
Sponsor
Boston Therapeutics
1. Study Identification
Unique Protocol Identification Number
NCT04569214
Brief Title
The Efficacy and Safety of PAZ320 on PPG and Insulin Blood Levels in Type II Diabetic Patients
Acronym
PAZ320
Official Title
A Comparative, Dose-Escalating, Placebo-Controlled Study of the Efficacy and Safety of PAZ320, Ingested Together With a Standard Meal on Post-Prandial Glucose and Insulin Blood Levels in Type II Diabetic Patients Treated With Metformin
Study Type
Interventional
2. Study Status
Record Verification Date
September 2020
Overall Recruitment Status
Withdrawn
Study Start Date
September 2012 (Actual)
Primary Completion Date
February 2013 (Anticipated)
Study Completion Date
February 2013 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boston Therapeutics
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to test the efficacy of PAZ320 in diabetic patients.
Detailed Description
The purpose of the present clinical study is to test the efficacy of two doses of PAZ320 in diabetic patients already on treatment with metformin, in order to assess and quantify its effect on postprandial glucose and insulin levels after a standard meal composed of rice, compared to placebo.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type II Diabetes
Keywords
PAZ320, Type II diabetes, Metformin, Galactomannan
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
A - Placebo Control
Arm Type
Placebo Comparator
Arm Description
4 tablets of placebo
Arm Title
B - PAZ320 Low Dose
Arm Type
Experimental
Arm Description
2 tablets of PAZ320 and 2 tablet of placebo
Arm Title
C - PAZ320 High Dose
Arm Type
Experimental
Arm Description
4 tablet of PAZ320
Intervention Type
Drug
Intervention Name(s)
PAZ320
Other Intervention Name(s)
Galactomannan
Intervention Description
Treatment arm B - 2 tablets of PAZ320 and 2 tablets of placebo, total of 4 tablets Treatment arm C - 4 tablets of PAZ320
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
Treatment arm A - 4 tablets of placebo Treatment arm B - 2 tablets of PAZ320 and 2 tablets of placebo, total of 4 tablets
Primary Outcome Measure Information:
Title
Assess the PAZ320 effect on postprandial blood glucose levels in type II diabetic patients.
Description
The extent and duration of PAZ320 effect on postprandial blood glucose levels in type II diabetic patients will be assessed under treatment with metformin, over 4 hours after the intake of a standard meal, using an implanted continuous glucose monitoring device.
Time Frame
2 weeks
Secondary Outcome Measure Information:
Title
Number of Subjects with Adverse Events as a Measure of Safety and Tolerability
Description
The secondary safety endpoint is number subjects with occurrences of following AEs: injury, surgery, accidents, or illnesses, and significant abnormalities in clinical laboratory values, psychological testing, or physical examination findings. In cases of surgical or diagnostic procedures, the condition/illness leading to such a procedure will be considered as the AE rather than the procedure itself.
Time Frame
2 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients diagnosed with type II diabetes since at least one year, not presenting any complications of their disease.
Patients under treatment with Metformin up to 3g/day, given twice or three times daily. Metformin doses should not exceed 3g/day, and should be well tolerated by the patients, its dose should have been stable for the last 3 months before inclusion in the study. Metformin should be taken in the morning of the visit only after the test meal is taken. The next doses of metformin will be taken with meals after the visit, in the habitual order the patient is used to take. The patients should not stop taking metformin during the study, but continue as usual, except that in the mornings of the visits, as the patients arrive in fasting conditions, metformin should be taken after the test meal. If a concomitant combination with an oral anti diabetic agent is given, because of elevated HbA1c levels, it should be taken together with metformin after the test meal.
Age - between 35 and 65, male and female.
Females should not be pregnant or breast feeding, women of child bearing potential should guarantee anti-contraceptive measures.
BMI (body mass index) - between 25 and 32.
Patients with glycated hemoglobin (HbA1c) lower than 9%, and higher than 6.5%, HbA1c will be determined in the first visit.
Patients who are able to collaborate during the entire duration of the study.
Exclusion Criteria:
Patients with other underlying diseases, such as cardiovascular disease, renal disease, peripheral vascular disease or any condition considered to be a complication of diabetes, should be excluded from this study.
Patients treated with insulin subcutaneous injections or with GLP-1 agonists, or by alpha-glucosidase inhibitors or by glinides should not be included in the study.
HbA1c higher than 9%, or lower than 6.5%
Women who are either pregnant or lactating
Participation in another clinical study in the month preceding recruitment into the study.
Patients who cannot guarantee compliance.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
LOÏK GEFFRAY, MD
Organizational Affiliation
Department Of Internal Medicine, Infectious Diseases And Diabetology Hopital Robert Bisson (Lisieux) Lisieux, Normandy, France
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Internal Medicine, Infectious Diseases and Diabetology Hopital Robert Bisson (Lisieux)
City
Lisieux
State/Province
Normandy
ZIP/Postal Code
14107
Country
France
12. IPD Sharing Statement
Learn more about this trial
The Efficacy and Safety of PAZ320 on PPG and Insulin Blood Levels in Type II Diabetic Patients
We'll reach out to this number within 24 hrs